The seasonal burden of influenza, coupled with the with the recent pandemic outbreaks of more pathogenic strains such as the 2009 and 2013 H1N1, underscores the critical need for understanding the pathophysiology of influenza injury. Vaccination remains a cornerstone in the prevention of infection. However, vaccine efficacy varies from 50-80 % in a healthy population and can be even lower in very young children, elderly populations and the immune compromised. Therefore, there is critical need for effective therapeutic regimens focused on reducing viral burden, decreasing inflammation and promoting lung/epithelial repair. We have recently identified IL-22 as an epithelial specific cytokine that i integral in lung epithelial repair. However, mechanisms through which it promotes lung repair are unresolved. The central hypothesis for this application is IL-22 production ameliorates both airway injury as well as diffuse alveolar destruction (DAD) after influenza induced injury. We hypothesize that IL-22 interacts directly on epithelial cells, reducing apoptosis and promoting epithelial migration, which in turn, reduces inflammation. Our rationale is that mice lacking IL-22 have defects in epithelial repair and decreased numbers of lung progenitor cells. Importantly, administration of IL-22 reduces injury and rescues mice from fatal influenza infection. Thus, IL-22/IL-22RA1 signaling can be exploited therapeutically to reduce lung injury during experimental influenza infection. This hypothesis will be tested by pursuing three specific aims. In the first am we will test the role of IL-22 in ameliorating airway injury and promoting epithelial repair of the upper and lower conducting airways. We will test this by utilizing IL-22Ra1fl/fl crossed to airway and epithelial specific cre lines. We will examine the protective role of IL-22 using airway specific IL-22 transgenic mouse, and examine the effects in an uninhibited environment using IL-22BP-/- mice. Finally we will determine the therapeutic/reparative effects by administering IL-22:Fc at different times after infection and examining airway repair.
The second aim will test our hypothesis that IL-22 signals through AKT and both canonical and non-canonical STAT3 pathways, using in vitro techniques in both human and mouse airway cells.
The third aim specific aim is designed to test the ability of IL-22 to reduce DAD by communicating with lung progenitor cells. We will study the interaction of IL-22 in alveolar repair through the use of our IL- 22Ra1floxed mice crossed with epithelial and progenitor cell specific cre lines. Further, the ability of IL-22 to induce progenitor cell populations in repair will be examined, as well as the therapeutic use of IL-22 during influenza induced DAD. The contribution of the project outlined here is to provide a detailed understanding of how IL-22 promotes epithelial repair in both the airways and lung parenchyma after injury. To our knowledge, there are no studies identifying cytokine/stem cell interactions in the lung during disease. Such studies would provide novel insight into how inflammatory cells promote epithelial repair and have potentially great impact on influenza as well as a number of diseases involving parenchymal injury such as IPF and COPD.

Public Health Relevance

Influenza is a disease that has a tremendous impact on both health and economy. The proposed research is relevant to public health because it investigates the use of a cytokine (IL-22) to reduce injury and promote recovery after influenza infection. Thus, the proposed research is relevant to the part of the NIH's mission that pertains to developing fundamental knowledge to reduce burdens of disease on humanity.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL122760-04
Application #
9407043
Study Section
Lung Cellular, Molecular, and Immunobiology Study Section (LCMI)
Program Officer
Caler, Elisabet V
Project Start
2017-01-01
Project End
2019-12-31
Budget Start
2018-01-01
Budget End
2019-12-31
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Tulane University
Department
Type
Schools of Medicine
DUNS #
053785812
City
New Orleans
State
LA
Country
United States
Zip Code
70118
Pociask, Derek A; Robinson, Keven M; Chen, Kong et al. (2017) Epigenetic and Transcriptomic Regulation of Lung Repair during Recovery from Influenza Infection. Am J Pathol 187:851-863
McAleer, Jeremy P; Nguyen, Nikki L H; Chen, Kong et al. (2016) Pulmonary Th17 Antifungal Immunity Is Regulated by the Gut Microbiome. J Immunol 197:97-107
Eddens, Taylor; Campfield, Brian T; Serody, Katelin et al. (2016) A Novel CD4+ T Cell-Dependent Murine Model of Pneumocystis-driven Asthma-like Pathology. Am J Respir Crit Care Med 194:807-820
Zheng, Mingquan; Horne, William; McAleer, Jeremy P et al. (2016) Therapeutic Role of Interleukin 22 in Experimental Intra-abdominal Klebsiella pneumoniae Infection in Mice. Infect Immun 84:782-9
Parks, Olivia B; Pociask, Derek A; Hodzic, Zerina et al. (2015) Interleukin-22 Signaling in the Regulation of Intestinal Health and Disease. Front Cell Dev Biol 3:85
Le, Tianming; Eisses, John F; Lemon, Kathryn L et al. (2015) Intraductal infusion of taurocholate followed by distal common bile duct ligation leads to a severe necrotic model of pancreatitis in mice. Pancreas 44:493-9